What will DelveInsight’s Ranibizumab Biosimilar Insights Report 2020 cover?

 DelveInsight’s, “Ranibizumab Biosimilar Insight, 2020,” report provides comprehensive insights about 20+ companies and 20+ marketed and pipeline drugs in Ranibizumab Biosimilars landscape.

· It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products.

· It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type.

· It further highlights the inactive pipeline products in this space. 

Geography Covered

· Global coverage

Request for a detailed sample copy of the report: https://www.delveinsight.com/sample-request/ranibizumab-biosimilars-insight

What is Ranibizumab?

· Ranibizumab is a monoclonal antibody fragment created from the same parent mouse antibody as bevacizumab.

· It is an anti-angiogenic that has been approved to treat the "wet" type of age-related macular degeneration, a common form of age-related vision loss.

· Its effectiveness is similar to that of bevacizumab.

· Ranibizumab was developed by Genentech and marketed by them in the United States, and elsewhere by Novartis, under the brand name Lucentis.

· It is often used for age-related wet macular degeneration. Its effectiveness is similar to that of bevacizumab and aflibercept.

Ranibizumab Biosimilars: Marketed Drugs

· Razumab: Intas Pharmaceuticals

Ranibizumab Biosimilars: Emerging Drugs

· SB-11: Samsung Bioepis

Click here and download free sample pages of the report.

Ranibizumab Therapeutic Assessment

1. Key pharma players involved:

· Xbrane

· Senju Pharmaceutical

· Samsung Bioepis

· Polus BioPharm

· PlantForm Corporation

· Pfenex

· Lupin

· Intas Biopharmaceuticals

· Ildong Pharmaceutical

· Harvest Moon Pharmaceuticals

· Gene Techno Science

· Coherus

· Chong Kun Dang

· Biocure Technology

· BIOCND

· Qilu Pharmaceuticals

· Bioeq

· Formycon

2. Key products developed:

· Xlucane

· SJP 0133

· SB-11

· PDP807

· PF582

· Razumab

· IDB-0062

· GBS-007

· CHS-3351

· CKD-701

· BCD 300

· FYB201

Read our detailed report @ https://www.delveinsight.com/report-store/ranibizumab-biosimilars-insight

Visit our repository of reports: https://www.delveinsight.com/report-store.php

Comments

Post a Comment

Popular posts from this blog

Beta-thalassemia Market Poised for Significant Growth with Novel Therapies and Rising Prevalence

The Beta-thalassemia market is set to experience remarkable growth in the coming years, driven by the increasing prevalence of the condition and the anticipated launch of innovative therapies. Leading players in the pharmaceutical and biotech industries, including Acceleron Pharma, Agios Pharmaceuticals, Bluebird Bio, and CRISPR Therapeutics, are working diligently to address unmet medical needs and expand treatment options. Download our sample pages @ https://www.delveinsight.com/report-store/beta-thalassemia-market?utm_source=report&utm_medium=promotion&utm_campaign=kpr Market Dynamics and Key Drivers Beta-thalassemia, a hereditary blood disorder caused by mutations in the HBB gene, results in reduced or absent synthesis of beta-globin chains in hemoglobin. This condition affects millions worldwide, with significant prevalence in regions such as the United States, Europe, and Asia. Recent advancements in diagnostics and a heightened focus on genetic counseling have contribute...
Read more

Growth of the Candidemia Market: Drivers, Developments, and Future Outlook (2024-2034)

Candidemia , a bloodstream infection caused by Candida species, poses significant health challenges, particularly among individuals with weakened immune systems. The global candidemia market is projected to experience a compound annual growth rate (CAGR) of 3.16% from 2024 to 2034. citeturn0search0 Market Drivers: Increasing Incidence: The rising number of immunocompromised patients, including those with HIV/AIDS, cancer, or organ transplants, has led to a higher prevalence of candidemia. Advancements in Diagnostics: The adoption of advanced diagnostic techniques, such as molecular assays and biomarker identification, facilitates swift and accurate detection of candidemia, enabling timely intervention and improved patient outcomes. Innovative Therapeutics: The development of novel antifungal medications and immune-based therapies offers enhanced efficacy and reduced adverse effects, contributing to market growth. To know more about candidemia market drivers, visit https://www.delvei...
Read more

Unlocking the Facts: C-Met Mutated Non-Small Cell Lung Cancer Epidemiology, Market Trends, and Leading Players

What is C-Met Mutated Non-small Cell Lung Cancer ? C-Met (also known as MET) is a gene that codes for a protein called the "hepatocyte growth factor receptor" (HGFR) or c-Met receptor. This receptor plays a crucial role in regulating cell growth, survival, migration, and invasion. When the c-Met gene is mutated, it can lead to the abnormal activation of signaling pathways that promote cancer development and progression. How is C-Met Mutated Non-small Cell Lung Cancer epidemiology segmented? C-Met Mutated Non-small Cell Lung Cancer epidemiology is segmented as C-Met Mutated Non-small Cell Lung Cancer Total Incident Cases, Age-specific C-Met Mutated Non-small Cell Lung Cancer cases, Gender-specific C-Met Mutated Non-small Cell Lung Cancer Cases, Stage-specific C-Met Mutated Non-small Cell Lung Cancer incident cases, Type-specific C-Met Mutated Non-small Cell Lung Cancer incident cases, and Total Treated C-Met Mutated Non-small Cell Lung Cancer Cases. What is the C-Met Mutated...
Read more